{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:30:49Z","timestamp":1788471049427,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Existing guidelines advocate an updated therapeutic algorithm for chronic neuropathic pain (NeP), but pharmacotherapeutic management should be individualized to pain phenotypes to achieve higher efficacy. This study was aimed to evaluate the efficacy of medications, based on NeP phenotypes, and to propose symptom-based pharmacotherapy. This retrospective study was enrolled 265 outpatients with chronic NeP related to spinal disorders. The patients were classified into three groups: spinal cord-related pain, radicular pain, and cauda equina syndrome. Data were obtained from patient-based questionnaires using Neuropathic Pain Symptom Inventory (NPSI) and the Brief Scale for Psychiatric Problems in Orthopaedic Patients, and from clinical information. The proportions of patients with \u2265\u00a030% and \u2265\u00a050% reduction in NPSI score for each pain subtype (spontaneous pain, paroxysmal pain, evoked pain, and paresthesia\/dysesthesia) and drugs were evaluated. The pain reduction rate was significantly lower in patients with spinal cord-related pain, especially for paresthesia\/dysesthesia. For spinal cord-related pain, duloxetine and neurotropin had insufficient analgesic effects, whereas mirogabalin was the most effective. Pregabalin or mirogabalin for radicular pain and duloxetine for cauda equina syndrome are recommended in cases of insufficient analgesic effects with neurotropin. The findings could contribute to better strategies for symptom-based pharmacotherapeutic management.<\/jats:p>","DOI":"10.1038\/s41598-022-11345-y","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T14:05:59Z","timestamp":1651586759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Symptom-based pharmacotherapy for neuropathic pain related to spinal disorders: results from a patient-based assessment"],"prefix":"10.1038","volume":"12","author":[{"given":"Hideaki","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Honjoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Matsumine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"11345_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1474-4422(14)70102-4","volume":"13","author":"TS Jensen","year":"2014","unstructured":"Jensen, T. S. & Finnerup, N. B. Allodynia and hyperalgesia in neuropathic pain: Clinical manifestations and mechanisms. Lancet Neurol. 13, 924\u2013935 (2014).","journal-title":"Lancet Neurol."},{"key":"11345_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"RD Treede","year":"2008","unstructured":"Treede, R. D. et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 70, 1630\u20131635 (2008).","journal-title":"Neurology"},{"key":"11345_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.pain.2010.02.034","volume":"149","author":"AH Doth","year":"2010","unstructured":"Doth, A. H., Hansson, P. T., Jensen, M. P. & Taylor, R. S. The burden of neuropathic pain: A systematic review and meta-analysis of health utilities. Pain 149, 338\u2013344 (2010).","journal-title":"Pain"},{"key":"11345_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ejp.977","volume":"21","author":"S Inoue","year":"2017","unstructured":"Inoue, S., Taguchi, T., Yamashita, T., Nakamura, M. & Ushida, T. The prevalence and impact of chronic neuropathic pain on daily and social life: A nationwide study in a Japanese population. Eur. J. Pain 21, 727\u2013737 (2017).","journal-title":"Eur. J. Pain"},{"key":"11345_CR5","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1212\/01.wnl.0000259085.61898.9e","volume":"68","author":"MP Jensen","year":"2007","unstructured":"Jensen, M. P., Chodroff, M. J. & Dworkin, R. H. The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology 68, 1178\u20131182 (2007).","journal-title":"Neurology"},{"key":"11345_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00776-013-0496-9","volume":"19","author":"T Yamashita","year":"2014","unstructured":"Yamashita, T., Takahashi, K., Yonenobu, K. & Kikuchi, S. Prevalence of neuropathic pain in cases with chronic pain related to spinal disorders. J. Orthop. Sci. 19, 15\u201321 (2014).","journal-title":"J. Orthop. Sci."},{"key":"11345_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/jgs.12848","volume":"62","author":"LH Eggermont","year":"2014","unstructured":"Eggermont, L. H. et al. Pain characteristics associated with the onset of disability in older adults: The maintenance of balance, independent living, intellect, and zest in the Elderly Boston Study. J. Am. Geriatr. Soc. 62, 1007\u20131016 (2014).","journal-title":"J. Am. Geriatr. Soc."},{"key":"11345_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pain.2010.07.031","volume":"152","author":"M Haanp\u00e4\u00e4","year":"2011","unstructured":"Haanp\u00e4\u00e4, M. et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 152, 14\u201327 (2011).","journal-title":"Pain"},{"key":"11345_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neurol.2018.08.005","volume":"175","author":"N Attal","year":"2019","unstructured":"Attal, N. Pharmacological treatments of neuropathic pain: The latest recommendations. Rev. Neurol. 175, 46\u201350 (2019).","journal-title":"Rev. Neurol."},{"key":"11345_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup, N. B. et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 14, 162\u2013173 (2015).","journal-title":"Lancet Neurol."},{"key":"11345_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","volume":"176","author":"X Moisset","year":"2020","unstructured":"Moisset, X. et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev. Neurol. 176, 325\u2013352 (2020).","journal-title":"Rev. Neurol."},{"key":"11345_CR12","volume-title":"Clinical Practice Guideline for Chronic Pain","author":"The Committee for Clinical Practice Guideline","year":"2018","unstructured":"The Committee for Clinical Practice Guideline. Clinical Practice Guideline for Chronic Pain (Shinko Trading Co. Ltd., 2018)."},{"key":"11345_CR13","volume-title":"Guidelines for the Pharmacologic Management of Neuropathic Pain","author":"The Committee for the Guidelines for the Pharmacologic Management of Neuropathic Pain (revised) of JSPC (Japan Society of Pain Clinicians)","year":"2016","unstructured":"The Committee for the Guidelines for the Pharmacologic Management of Neuropathic Pain (revised) of JSPC (Japan Society of Pain Clinicians). Guidelines for the Pharmacologic Management of Neuropathic Pain (Shinko Trading Co. Ltd., 2016)."},{"key":"11345_CR14","doi-asserted-by":"crossref","unstructured":"Harden, R. N. Chronic neuropathic pain. Mechanisms, diagnosis, and treatment. Neurologist 11, 111\u2013122 (2005).","DOI":"10.1097\/01.nrl.0000155180.60057.8e"},{"key":"11345_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/sj.sc.3101824","volume":"44","author":"PJ Siddall","year":"2006","unstructured":"Siddall, P. J. & Middleton, J. W. A proposed algorithm for the management of pain following spinal cord injury. Spinal Cord. 44, 67\u201377 (2006).","journal-title":"Spinal Cord."},{"key":"11345_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/PHM.0000000000000382","volume":"95","author":"K Min","year":"2016","unstructured":"Min, K., Oh, Y., Lee, S. H. & Ryu, J. S. Symptom-based treatment of neuropathic pain in spinal cord-injured patients: A randomized crossover clinical trial. Am. J. Phys. Med. Rehabil. 95, 330\u2013338 (2016).","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"11345_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","volume":"338","author":"M Kremer","year":"2016","unstructured":"Kremer, M. et al. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience. 338, 183\u2013206 (2016).","journal-title":"Neuroscience."},{"key":"11345_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jos.2021.08.016","author":"H Nakajima","year":"2021","unstructured":"Nakajima, H. et al. Symptom-based characteristics and treatment efficacy of neuropathic pain related to spinal disorders. J. Orthop. Sci. https:\/\/doi.org\/10.1016\/j.jos.2021.08.016 (2021).","journal-title":"J. Orthop. Sci."},{"key":"11345_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.pain.2003.12.024","volume":"108","author":"D Bouhassira","year":"2004","unstructured":"Bouhassira, D. et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108, 248\u2013257 (2004).","journal-title":"Pain"},{"key":"11345_CR20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jos.2019.01.012","volume":"24","author":"H Nakajima","year":"2019","unstructured":"Nakajima, H. et al. Multicenter cross-sectional study of the clinical features and types of treatment of spinal cord-related pain syndrome. J. Orthop. Sci. 24, 798\u2013804 (2019).","journal-title":"J. Orthop. Sci."},{"key":"11345_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.22603\/ssrr.2018-0096","volume":"3","author":"H Nakajima","year":"2019","unstructured":"Nakajima, H., Uchida, K., Takayasu, M. & Ushida, T. A nationwide survey of spinal cord-related pain syndrome in Japan: Clinical characteristics and treatment. Spine Surg. Relat. Res. 3, 319\u2013326 (2019).","journal-title":"Spine Surg. Relat. Res."},{"key":"11345_CR22","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","volume":"60","author":"RH Dworkin","year":"2003","unstructured":"Dworkin, R. H. et al. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 60, 1274\u20131283 (2003).","journal-title":"Neurology"},{"key":"11345_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2377-8-33","volume":"8","author":"JC Arezzo","year":"2008","unstructured":"Arezzo, J. C. et al. Efficacy and safety of pregabalin 600 mg\/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial. BMC Neurol. 8, 33 (2008).","journal-title":"BMC Neurol."},{"key":"11345_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1212\/WNL.0b013e318281546b","volume":"80","author":"DD Cardenas","year":"2013","unstructured":"Cardenas, D. D. et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology 80, 533\u2013539 (2013).","journal-title":"Neurology"},{"key":"11345_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks, E. D. Mirogabalin: First global approval. Drugs 79, 463\u2013468 (2019).","journal-title":"Drugs"},{"key":"11345_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon, Y. et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J. Pharmacol. Exp. Ther. 365, 573\u2013582 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"11345_CR27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","volume":"160","author":"J Kato","year":"2019","unstructured":"Kato, J. et al. Mirogabalin for the management of postherpetic neuralgia: A randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain 160, 1175\u20131185 (2019).","journal-title":"Pain"},{"key":"11345_CR28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdi.13013","volume":"10","author":"M Baba","year":"2019","unstructured":"Baba, M. et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients. J. Diabetes Investig. 10, 1299\u20131306 (2019).","journal-title":"J. Diabetes Investig."},{"key":"11345_CR29","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1080\/14656566.2019.1651840","volume":"20","author":"T Ushida","year":"2019","unstructured":"Ushida, T. et al. Recent prescription status of oral analgesics in Japan in real-world clinical settings: Retrospective study using a large-scale prescription database. Expert Opin. Pharmacother. 20, 2041\u20132052 (2019).","journal-title":"Expert Opin. Pharmacother."},{"key":"11345_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4103\/0970-9185.83672","volume":"27","author":"DK Baidya","year":"2011","unstructured":"Baidya, D. K. et al. Pregabalin in acute and chronic pain. J. Anaesthesiol. Clin. Pharmacol. 27, 307\u2013314 (2011).","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"11345_CR31","doi-asserted-by":"publisher","first-page":"e21976","DOI":"10.1097\/MD.0000000000021976","volume":"99","author":"J Kato","year":"2020","unstructured":"Kato, J. et al. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial. Medicine 99, e21976 (2020).","journal-title":"Medicine"},{"key":"11345_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13018-020-01709-3","volume":"15","author":"T Tetsunaga","year":"2020","unstructured":"Tetsunaga, T. et al. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: A retrospective study. J. Orthop. Surg. Res. 15, 191 (2020).","journal-title":"J. Orthop. Surg. Res."},{"key":"11345_CR33","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke, J. F. et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67, 1411\u20131420 (2006).","journal-title":"Neurology"},{"key":"11345_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","volume":"6","author":"J Raskin","year":"2005","unstructured":"Raskin, J. et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 6, 346\u2013356 (2005).","journal-title":"Pain Med."},{"key":"11345_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/jdi.12361","volume":"7","author":"H Yasuda","year":"2016","unstructured":"Yasuda, H. et al. Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study. J. Diabetes Investig. 7, 100\u2013108 (2016).","journal-title":"J. Diabetes Investig."},{"key":"11345_CR36","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith, E. M. et al. Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 309, 1359\u20131367 (2013).","journal-title":"JAMA"},{"key":"11345_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/papr.12127","volume":"14","author":"TL Vollmer","year":"2014","unstructured":"Vollmer, T. L. et al. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract. 14, 732\u2013744 (2014).","journal-title":"Pain Pract."},{"key":"11345_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.7224\/1537-2073.2014-001","volume":"17","author":"TR Brown","year":"2015","unstructured":"Brown, T. R. & Slee, A. A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis. Int. J. MS Care 17, 83\u201389 (2015).","journal-title":"Int. J. MS Care"},{"key":"11345_CR39","doi-asserted-by":"publisher","first-page":"650","DOI":"10.31616\/asj.2020.0191","volume":"15","author":"O Tsuji","year":"2021","unstructured":"Tsuji, O. et al. Effectiveness of duloxetine for postsurgical chronic neuropathic disorders after spine and spinal cord surgery. Asian Spine J. 15, 650\u2013658 (2021).","journal-title":"Asian Spine J."},{"key":"11345_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ejp.1125","volume":"22","author":"K Minami","year":"2018","unstructured":"Minami, K. et al. Effects of duloxetine on pain and walking distance in neuropathic pain models via modulation of the spinal monoamine system. Eur. J. Pain. 22, 355\u2013369 (2018).","journal-title":"Eur. J. Pain."},{"key":"11345_CR41","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1213\/01.ANE.0000160582.25368.B9","volume":"101","author":"T Suzuki","year":"2005","unstructured":"Suzuki, T., Li, Y. H. & Mashimo, T. The antiallodynic and antihyperalgesic effects of neurotropin in mice with spinal nerve ligation. Anesth. Analg. 101, 793\u2013799 (2005).","journal-title":"Anesth. Analg."},{"key":"11345_CR42","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1212\/WNL.50.6.1842","volume":"50","author":"Y Harati","year":"1998","unstructured":"Harati, Y. et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50, 1842\u20131846 (1998).","journal-title":"Neurology"},{"key":"11345_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0304-3959(03)00020-4","volume":"104","author":"F Boureau","year":"2003","unstructured":"Boureau, F., Legallicier, P. & Kabir-Ahmadi, M. Tramadol in post-herpetic neuralgia: A randomized, double-blind, placebo-controlled trial. Pain 104, 323\u2013331 (2003).","journal-title":"Pain"},{"key":"11345_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/AJP.0b013e31818a744d","volume":"25","author":"C Norrbrink","year":"2009","unstructured":"Norrbrink, C. & Lundeberg, T. Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Clin. J. Pain 25, 177\u2013184 (2009).","journal-title":"Clin. J. Pain"},{"key":"11345_CR45","doi-asserted-by":"publisher","first-page":"230949901772794","DOI":"10.1177\/2309499017727945","volume":"25","author":"K Sugai","year":"2017","unstructured":"Sugai, K., Tsuji, O., Matsumoto, M., Nishiwaki, Y. & Nakamura, M. Chronic musculoskeletal pain in Japan (the final report of the 3-year longitudinal study): Association with a future decline in activities of daily living. J. Orthop. Surg. 25, 2309499017727945 (2017).","journal-title":"J. Orthop. Surg."},{"key":"11345_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00776-010-0012-4","volume":"16","author":"K Yoshida","year":"2011","unstructured":"Yoshida, K. et al. A validation study of the Brief Scale for Psychiatric problems in Orthopaedic Patients (BS-POP) for patients with chronic low back pain (verification of reliability, validity, and reproducibility). J. Orthop. Sci. 16, 7\u201313 (2011).","journal-title":"J. Orthop. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11345-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:23:37Z","timestamp":1669343017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11345-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11345"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11345-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7192"}}